Balyasny Asset Management LLC Verve Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 42,415 shares of VERV stock, worth $234,554. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,415
Previous 89,248
52.48%
Holding current value
$234,554
Previous $435,000
52.87%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VERV
# of Institutions
185Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$68.3 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$36.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$27.4 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$23.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$22.1 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $331M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...